| Name | Title | Contact Details |
|---|
Biomea Fusion, Inc. was formed in 2017 by a small group of biotech executives. We are dedicated to developing innovative medicines for patients. It is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care.
Natural molecules or derivatives make up more than half of the current drugs on the market with applications to nearly every disease known to humans. Salicylic acid, morphine, cannabinoids and insulin are a few examples. Our specialty is in producing these, and new targets, using a fast and scalable platform based on engineered microbes.
Tempest Therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways.
Pascal Biosciences is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The company`s leading cannabinoid portfolio comprises a small molecule therapeutic, ST-403, that is advancing into clinical trials for the treatment of glioblastoma, and an immuno-stimulatory molecule. In addition, Pascal Biosciences is developing a B-cell targeted antibody for acute lymphoblastic leukemia and an antibody for calcium channels expressed by the immune system. Pascal is headquartered in Vancouver, Canada. The company trades on the TSX Venture Exchange under the symbol “PAS”.
xbiotech usa inc is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.